Effects of direct renal arterial infusion of bufalin and ouabain in conscious sheep.
1. The presence of an endogenous digitalis-like factor (EDLF) in the plasma of both normal and volume expanded animals is well documented. In this study we have used ouabain and bufalin as pharmacological analogues to mimic the renal effects of EDLF and to investigate whether any interaction occurs between atrial natriuretic factor (ANF) and EDLF. 2. Conscious Na replete sheep with chronically indwelling catheters in the renal artery received renal arterial infusion of ouabain (1000 micrograms h-1) or bufalin (500 micrograms h-1) for 60 min. Renal arterial infusion of bufalin increased sodium excretion (UNaV) from 120 +/- 13 to 596 +/- 161 mumol min-1 after 45 min. Bufalin infusion did not alter glomerular filtration rate (GFR), effective renal plasma flow (ERPF), or lithium clearance. Ouabain infusion increased UNaV from 124 +/- 57 to 764 +/- 123 mumol min-1 in the first hour after infusion. 3. ANF infusion increased UNaV from 159 +/- 34 to 583 +/- 134 mumol min-1. When renal arterial bufalin infusion was followed by renal arterial ANF infusion (50 micrograms h-1) UNaV was increased from 155 +/- 31 to 795 +/- 96 mumol min-1. This increase in UNaV is approximately equal to the sum of the separate effects of bufalin and ANF. 4. The natriuretic effects of ouabain at pharmacological doses in sheep are confirmed by this study. The data presented here do not support the hypothesis that EDLF sensitizes the kidney to the natriuretic effects of ANF.
Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Parkville, Australia.
N A
NA
Yates
J G
JG
McDougall
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001798:Blood Proteins / Q000494:pharmacology; D002018:Bufanolides / Q000008:administration & dosage / Q000494:pharmacology*; D002298:Cardenolides; D004077:Digoxin; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007261:Infusions, Intra-Arterial; D009318:Natriuresis / Q000187:drug effects*; D010042:Ouabain / Q000008:administration & dosage / Q000494:pharmacology*; D011188:Potassium / Q000652:urine; D012077:Renal Artery; D012079:Renal Circulation / Q000187:drug effects; D012503:Saponins; D012756:Sheep; D012964:Sodium / Q000652:urine; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors
D001798:Blood Proteins; D002018:Bufanolides; D002298:Cardenolides; D012503:Saponins; C034504:digoxin-like factors; D010042:Ouabain; D004077:Digoxin; D009320:Atrial Natriuretic Factor; D012964:Sodium; D000254:Sodium-Potassium-Exchanging ATPase; D011188:Potassium; C022777:bufalin